6. Wang G, He Y, Sun Y, et al. Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer. Clin Transl Oncol. 2020;22(6):813-822. doi:10.1007/s12094-019-02213-9 7. Yoshikawa A, Nakamura Y....
Methods: Records of HER2+ BC treated in 2000–2017 were reviewed. Results: 283/1171 (24%) HER2+ BC patients developed metastatic disease. 109/283 patients (39%) have CNSm associated with worse prognosis and increased risk of death (hazard ratio: 4.7; 95% CI: 3.5–6.4). Prognostic ...
[11]Kurozumi S, Padilla M, Kurosumi M, et al. HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients. Breast Cancer Res Treat. 2016;158(1):99-111. [12]van Mackelenbergh MT, Loibl S, Untch ...
[9] Darlix A, Louvel G, Fraisse J, et al. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br J Cancer. 2019,121 (12), 991–1000. [10] Hackshaw MD, Danysh HE, Henderson...
Triple-negative breast cancers (TNBCs) are associated with a poor prognosis. In contrast to other molecular subtypes, they have no identified specific targ... M M-Rabet,O Cabaud,E Josselin,... - 《Annals of Oncology》 被引量: 3发表: 2016年 NECTIN-4 FOR TARGET GENES OF CANCER THERAPY ...
trialcompletedrecruitmentwasnumericallybetterwithpertuzumabplustrastuzumabthanwithtrastuzumabalone.Withsurvivalratesofalmost5yearsinwomenwithmetastaticHER2-positivebreastcancerand75%ofpatientsachievingapathologicalcompleteresponse,newtreatmentsinthepastdecadehaveclearlyimprovedtheprognosisofHER2-positivebreastcancer.Despitethese...
16. Loibl S, Untch M, Buyse M, et al. Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC). Cancer Res. 2020;80(4_Suppl):P5-06-02.
Expression of CD44+/CD24 was found to be an independent negative indicator for prognosis and a predictive marker for trastuzumab response in HER2-postive primary breast cancers, although not in metastatic breast cancer. Further investigations on the clinical implications of BCSCs in HER2-positive ...
[17]Kim MH, Kim GM, Kim JH, Kim JY, Park HS, Park S, et al.. Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older. Breast Canc...
[3]Harbeck N. Advances in targeting HER2-positive breast cancer. Curr Opin Obstet Gynecol. 2018;30(1):55-59. [4]Giordano SH, Buzdar AU, Smithet TL, al. Is breast cancer survival improving? Cancer. 2004;100(1):44-...